Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abbreviated MRI with Dotarem for Breast Cancer
NCT04341129Phase 1Completed
- Sponsor
- University of Chicago
- Start
- Jul 2020
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gadoterate meglumine in breast cancer, sponsored by University of Chicago. Primary endpoint: Diagnostic accuracy of dynamic contrast-enhanced breast MRIs. Started Jul 2020; status: completed.
02
Drugs
gadoterate meglumine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04341129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04341129.